Voyager Therapeutics: Undervalued Growth Potential Amidst Strong Financials and Strategic Advancements

In a report released yesterday, Sumant Kulkarni from Canaccord Genuity maintained a Buy rating on Voyager Therapeutics (VYGR – Research Report), with a price target of $12.00.

Sumant Kulkarni has given his Buy rating due to a combination of factors that highlight Voyager Therapeutics’ potential for growth. The company is seen as undervalued, especially with several internal and external catalysts anticipated in the coming years, which could significantly impact its valuation. Despite a challenging market environment and a notable stock pullback, the company’s cash runway remains strong, extending into mid-2027, providing a stable financial foundation.
Additionally, Voyager Therapeutics is making progress in its key programs, such as the ongoing multiple ascending dose study for its anti-tau monoclonal antibody aimed at treating Alzheimer’s disease. The company is also expected to present promising preclinical data at an upcoming conference, and its partnerships, particularly with NBIX, are advancing with potential investigational new drug applications in the pipeline. These developments, combined with external collaborations validating their TRACER capsid technology, support the positive outlook and the maintained price target of $12.

Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of VYGR in relation to earlier this year.